CO6290681A2 - Nanodispersion - Google Patents

Nanodispersion

Info

Publication number
CO6290681A2
CO6290681A2 CO10089145A CO10089145A CO6290681A2 CO 6290681 A2 CO6290681 A2 CO 6290681A2 CO 10089145 A CO10089145 A CO 10089145A CO 10089145 A CO10089145 A CO 10089145A CO 6290681 A2 CO6290681 A2 CO 6290681A2
Authority
CO
Colombia
Prior art keywords
nanodispersion
nanoparticles
salts
water
derivatives
Prior art date
Application number
CO10089145A
Other languages
English (en)
Inventor
Ajay Jaysihgh Khopade
Subhas Balaram Bhowmick
N Arulsudar
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290681(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of CO6290681A2 publication Critical patent/CO6290681A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

La presente invención proporciona una nanodispersión que comprende nanopartículas que tienen un tamaño promedio menos de 300 nm dispersadas en un vehículo que comprende un solvente miscible con agua y agua, dichas nanopartículas que comprenden uno o más derivados taxano, un polímero y un surfactante que comprende una mezcla de ácidos grasos o sus sales y esterol o sus derivados o sus sales.
CO10089145A 2007-12-24 2010-07-22 Nanodispersion CO6290681A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2527MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
CO6290681A2 true CO6290681A2 (es) 2011-06-20

Family

ID=40853553

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10089145A CO6290681A2 (es) 2007-12-24 2010-07-22 Nanodispersion

Country Status (20)

Country Link
US (2) US8586062B2 (es)
EP (2) EP2231144B1 (es)
JP (2) JP5656643B2 (es)
KR (1) KR101505419B1 (es)
CN (1) CN101909614B (es)
AP (1) AP2895A (es)
AU (1) AU2008346121B2 (es)
BR (1) BRPI0821514B8 (es)
CA (1) CA2710525C (es)
CO (1) CO6290681A2 (es)
DK (1) DK2231144T3 (es)
EA (1) EA016434B1 (es)
ES (1) ES2509490T3 (es)
IL (1) IL206584A0 (es)
MX (1) MX2010007076A (es)
NZ (1) NZ586343A (es)
PL (1) PL2231144T3 (es)
UA (1) UA100543C2 (es)
WO (1) WO2009087678A2 (es)
ZA (1) ZA201004450B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201270050A1 (ru) * 2009-06-19 2012-05-30 Сан Фарма Адвансед Ресёрч Компани Лтд. Нанодисперсия лекарственного средства и способ ее получения
CN102038635A (zh) * 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
ES2385995B2 (es) * 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
CN102078300B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 托拉塞米脂质体固体制剂
CN102366409B (zh) * 2011-09-14 2013-03-20 海南灵康制药有限公司 一种尼扎替丁脂质体固体制剂
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10736327B2 (en) * 2013-03-14 2020-08-11 Griffith Foods International Inc. Natural fungicide composition
WO2015184238A1 (en) * 2014-05-30 2015-12-03 Oms Investments, Inc. Nano-sized water-based dispersion compositions and methods of making thereof
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
EP3307242A4 (en) * 2015-06-09 2019-01-23 Sun Pharma Advanced Research Company Limited PICn-01
CN107551390A (zh) * 2017-08-21 2018-01-09 常熟佳禾生物科技有限公司 一种用于治疗乳腺小叶增生的中药文胸贴片及其制备方法
MX2020009629A (es) 2018-03-19 2021-01-08 Epicyt Pharma Ab Una composición para su uso en el tratamiento de afecciones provocadas por la carencia de calcio.
US11423574B2 (en) 2019-12-17 2022-08-23 Emma Ruccio Method and apparatus for detecting scoliosis
US11877717B2 (en) 2019-12-17 2024-01-23 Emma Ruccio Method and apparatus for detecting scoliosis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018A (en) * 1849-01-09 Improvement in bog-cutters
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR19990075621A (ko) * 1998-03-23 1999-10-15 임성주 경사 평판형 배양조
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE60032372T2 (de) * 1999-09-23 2007-10-11 Dabur Pharma Ltd., New Delhi Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
TWI230616B (en) 2000-09-25 2005-04-11 Ind Tech Res Inst Liposome for incorporating large amounts of hydrophobic substances
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
DE10124952A1 (de) * 2001-05-21 2002-12-12 Bayer Ag Verfahren zur Herstellung von Nanodispersionen
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20050288521A1 (en) * 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
MX2007010394A (es) * 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
BRPI0617663A2 (pt) * 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof

Also Published As

Publication number Publication date
US20100297244A1 (en) 2010-11-25
PL2231144T3 (pl) 2014-12-31
AP2010005314A0 (en) 2010-08-31
AU2008346121A1 (en) 2009-07-16
ES2509490T3 (es) 2014-10-17
EA201070793A1 (ru) 2010-12-30
AP2895A (en) 2014-05-31
NZ586343A (en) 2012-03-30
CN101909614A (zh) 2010-12-08
AU2008346121B2 (en) 2013-10-10
WO2009087678A2 (en) 2009-07-16
CN101909614B (zh) 2015-04-15
DK2231144T3 (da) 2014-10-13
WO2009087678A3 (en) 2009-09-11
KR20100112564A (ko) 2010-10-19
BRPI0821514B1 (pt) 2020-03-10
KR101505419B1 (ko) 2015-03-30
CA2710525C (en) 2017-08-22
JP5937180B2 (ja) 2016-06-22
EA016434B1 (ru) 2012-04-30
BRPI0821514B8 (pt) 2021-05-25
BRPI0821514A2 (pt) 2016-09-27
IL206584A0 (en) 2010-12-30
JP5656643B2 (ja) 2015-01-21
CA2710525A1 (en) 2009-07-16
EP2853264A1 (en) 2015-04-01
ZA201004450B (en) 2011-03-30
JP2011507946A (ja) 2011-03-10
EP2231144A4 (en) 2011-01-12
UA100543C2 (ru) 2013-01-10
MX2010007076A (es) 2010-09-30
JP2015110565A (ja) 2015-06-18
US20140030352A1 (en) 2014-01-30
EP2231144B1 (en) 2014-07-02
US8586062B2 (en) 2013-11-19
EP2231144A2 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
CO6290681A2 (es) Nanodispersion
EA201270050A1 (ru) Нанодисперсия лекарственного средства и способ ее получения
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
CO2017012265A2 (es) Fluidos de perforación y métodos de uso
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
PA8825201A1 (es) Dispositivo de suministro de medicación
PL1957041T3 (pl) Emulsja olej-w-wodzie i jej zastosowanie dla nadania funkcji
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
AR055351A1 (es) Metodos y composiciones para el control de finos de formacion y para la reduccion de reflujo de agente de sosten
BR112012031500A8 (pt) Composições sólidas
BR112015024274A2 (pt) agente antiestático, composição de agente antiestático, composição de resina antiestática e artigo moldado
BR112013028400A2 (pt) nanocompósitos de tereftalato de polietileno-grafeno
BRPI0922018A2 (pt) métodos implementado por computador e sistema configurado para gerar imagens relativas a uma região subterrânea.
BRPI0815828A2 (pt) Formulação de emulsão que impede interação através da interface água-óleo
CL2007002952A1 (es) Polvo seco de nanoparticulas polimericas que comprende que se prepara polimerizando un monomero o dos o mas monomeros, en un liquido polar o una mezcla de dos o mas liquidos miscibles y un tensioactivo para producir nanoparticulas polimericas, elimin
EA201270354A1 (ru) Полимерные добавки для расширения технических возможностей технологических жидкостей, содержащих вязкоупругие пав, и способы их применения
BRPI0923507A2 (pt) motor e dispositivo elétrico que usa o mesmo.
BR112015012916A2 (pt) uso de composição para reduzir a exsudação e a migração através de um filme solúvel em água
ATE434944T1 (de) Farbstoff-emulsion und emulgatorzusammensetzung sowie deren verwendung
BR112012010237A2 (pt) sistema de revestimento de um componente, emprego do mesmo e marcação de estradas
ES2531004T3 (es) Materiales dentales dotados de principio(s) activo(s) antiplaca
ES2634034T3 (es) Composiciones nutricionales con copos de fruta que contienen ácido docosahexenoico
AR061552A1 (es) Tapones punctales para el suministro de agentes activos
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas

Legal Events

Date Code Title Description
FC Application refused